CN103340874B - The application of Myriberine A in the anti-aseptic inflammation medicine of preparation - Google Patents
The application of Myriberine A in the anti-aseptic inflammation medicine of preparation Download PDFInfo
- Publication number
- CN103340874B CN103340874B CN201310331712.7A CN201310331712A CN103340874B CN 103340874 B CN103340874 B CN 103340874B CN 201310331712 A CN201310331712 A CN 201310331712A CN 103340874 B CN103340874 B CN 103340874B
- Authority
- CN
- China
- Prior art keywords
- myriberine
- inflammation
- swelling
- group
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AVUOIHDZVXMQNT-LGEZUQEUSA-N myriberine a Chemical compound C([C@@H]1CCC2)N3CCCC[C@H]3N3[C@@H]1[C@@H]2C[C@H]1CC(=O)C=C13 AVUOIHDZVXMQNT-LGEZUQEUSA-N 0.000 title claims abstract description 78
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 6
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 description 19
- 241000700159 Rattus Species 0.000 description 13
- 210000002683 foot Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 238000003304 gavage Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241001540861 Mycetia faberi Species 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to Myriberine A and preparing the application in anti-inflammatory drug, described inflammation is aseptic inflammation, and described Myriberine A has good antiinflammatory, antiinflammation.The Myriberine A that the present invention relates to belongs to first public preparing the purposes in anti-inflammatory drug, because framework types belongs to brand-new framework types, and its inhibit activities for inflammation is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for antiinflammatory, obviously there is significant progress simultaneously.
Description
Technical field
The present invention relates to the novelty teabag of compound Myriberine A, particularly relate to the application of Myriberine A in the anti-aseptic inflammation medicine of preparation.
Background technology
Inflammation occurs in local, also can affect whole body simultaneously.Local clinical feature be red, hot, swollen, pain and dysfunction.Red, heat is caused by inflammation local vascular dilation, blood flow are accelerated.Swollen is because local inflammation is congested, flow components oozes out and causes.The medicine that research and development have an antiinflammatory action for alleviation checking, palliate the agonizing sufferings significant.
The compound Myriberine A that the present invention relates to is one and delivers (Sheng-Dian Huang in 2012, et al., Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton from Myrioneuron faberi.Organic Letters, 2012, 3 (15), 590 – 593.) noval chemical compound, this compound has brand-new framework types, current purposes only relates to and suppresses hepatitis C virus (Sheng-Dian Huang, et al., Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton from Myrioneuron faberi.Organic Letters, 2012, 3 (15), 590 – 593.), the purposes of the Myriberine A that the present invention relates in the anti-aseptic inflammation medicine of preparation belongs to first public.
Summary of the invention
The object of this invention is to provide Myriberine A and prepare the application in anti-inflammatory drug.
Described inflammation is aseptic inflammation.
Described compound Myriberine A structure is as shown in formula I:
Myriberine A is to prepare the beneficial effect applied in anti-inflammatory drug as follows:
First demonstrate Myriberine A and there is effective antiinflammatory effect.Have employed the classical mice ear model caused by dimethylbenzene and rat agar foot swelling model, observe the Myriberine A of various dose within a certain period of time to the antiinflammatory action of laboratory animal.Research shows:
1, the mice ear caused by Myriberine A xylol has obvious inhibitory action, and the suppression ratio of Myriberine A to swelling is obvious dose-dependence, and inhibitory action increases with the increase of dosage.
2, Myriberine A has obvious inhibitory action to the foot swelling of rat agar.
The Myriberine A that the present invention relates to belongs to first public preparing the purposes in anti-inflammatory drug, because framework types belongs to brand-new framework types, and its inhibit activities for inflammation is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for antiinflammatory, obviously there is significant progress simultaneously.
Detailed description of the invention
The preparation method of compound Myriberine A involved in the present invention is see document (Sheng-Dian Huang, et al., Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton from Myrioneuron faberi.Organic Letters, 2012,3 (15), 590 – 593.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound Myriberine A tablet involved in the present invention:
Get 5 g of compound Myriberine A, add 195 grams, dextrin, mixing, Conventional compression makes 1000.
Embodiment 2: the preparation of compound Myriberine A capsule involved in the present invention:
Get 5 g of compound Myriberine A, add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Test example 1:Myriberine A antiinflammatory pharmacodynamic study
Test material
1. Kunming (KM) plants mice: male, 6 weeks, and 18.5-22.5g is provided by Jiangsu Province's Experimental Animal Center.
2. rat (Wistar): male, weight 140 ~ 160g, is provided by Jiangsu Province's Experimental Animal Center.
Test method
1. gavage Myriberine A is to the effect of mouse ear inflammation: getting quality is 18.5 ~ 22.5g healthy male mice 50, is divided into 5 groups at random, often organizes 10.Myriberine A is little, in, heavy dose of group (1.0,2.5,6.25mgkg-1), aspirin group (200mgkg-1), blank group (normal saline).Gastric infusion respectively, continuous 7d, 1h after the 7th day gavage, 5 groups of mices are all evenly coated with dimethylbenzene 0.02mL forward and backward of mouse right ear, prepare auricle inflammatory model.After 1h, mice is put to death in collare dislocation, cuts two ears, lay round auricle respectively, weigh and be accurate to 0.0001g with diameter 8mm card punch at the same position of two ears along auricle baseline.Another name quality is divided immediately with electronic balance, of poor quality as swelling using left and right two ear, and calculate its swelling and suppression ratio.
Swelling=auris dextra sheet weight-left auricle weight
Suppression ratio=(the average swelling of matched group-average swelling of administration group) average swelling * 100% of/matched group
Experimental result:
1. gavage Myriberine A is to the effect of rat agar foot swelling: get the healthy male Wistar rat 40 of weight 140 ~ 160g, be divided into 5 groups at random.Myriberine A is little, in, heavy dose of group (1.0,2.5,6.25mgkg-1), aspirin group (200mgkg-1), blank group (normal saline).Respectively gastric infusion, continuous 7d, 1h after the 7th day gavage, the right back foot of the rat subcutaneous injection 10g/L agar 0.1mL that wastes time prepares the swollen acute inflammation model of foot, surveys its right back sufficient normal volume with rat foot cubic content measurement instrument.Cause scorching after 1,3,5,8,24h measures the right back sufficient volume of each Mus respectively, and calculates swelling.
2, Myriberine A topical is on the impact of mouse ear inflammation
After causing inflammation, there is highly red and swollen phenomenon in each group mouse right ear at once.Aspirin group and the mice ear caused by Myriberine A group xylol all have obvious inhibitory action, and the suppression ratio of Myriberine A to swelling is obvious dose-dependence, and inhibitory action increases with the increase of dosage, the results are shown in Table 1.
The impact (x ± s) of table 1Myriberine A xylol induced mice auricle edema
Compare with model group, * * P<0.01 * P<0.05
3, Myriberine A topical is on the impact of rat agar to foot swelling
After injection agar, each group rat foot claw all has tissue phenomenon to a certain degree.Under perusal, model group swelling is rubescent the most obvious, and slightly swelling is without obvious redness phenomenon for aspirin group, and Myriberine A group situation is between therebetween.Rat foot claw thickness all peaks when 3h, all slowly declines after 3h.Prolongation in time, each group of rat group turns swelling and is all diminishing, the swelling inhibitory action of aspirin group is the strongest, Myriberine A all has inhibitory action (p<0.05) to swollen 1,3, the 5 hour inflammation of rat foot, within 8 hours and 24 hours, compare zero difference with model group, in table 2.
Table 2Myriberine A is on the impact (x ± s) of rat agar toes swelling
Compare with model group, * * P<0.01 * P<0.05
Conclusion: the mice ear caused by Myriberine A xylol has obvious inhibitory action; Myriberine A has obvious inhibitory action to the foot swelling of rat agar.Myriberine A may be used for preparing anti-inflammatory drug.
Claims (1)
- The application of 1.Myriberine A in the anti-aseptic inflammation medicine of preparation, described compound Myriberine A structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310331712.7A CN103340874B (en) | 2013-08-01 | 2013-08-01 | The application of Myriberine A in the anti-aseptic inflammation medicine of preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310331712.7A CN103340874B (en) | 2013-08-01 | 2013-08-01 | The application of Myriberine A in the anti-aseptic inflammation medicine of preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103340874A CN103340874A (en) | 2013-10-09 |
| CN103340874B true CN103340874B (en) | 2015-09-09 |
Family
ID=49275736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310331712.7A Active CN103340874B (en) | 2013-08-01 | 2013-08-01 | The application of Myriberine A in the anti-aseptic inflammation medicine of preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103340874B (en) |
-
2013
- 2013-08-01 CN CN201310331712.7A patent/CN103340874B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton from Myrioneuron faberi;Sheng-Dian Huang等;《ORGANIC LETTERS》;20130115;第15卷(第3期);第590-593页 * |
| 生物碱类化合物药理作用研究进展;蒙其淼等;《时针国医国药》;20031231;第14卷(第11期);第700-702页 * |
| 马爱瑛.生物碱的提取与分离.《固原师专学报(自然科学)》.2006,第27卷(第3期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103340874A (en) | 2013-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103340874B (en) | The application of Myriberine A in the anti-aseptic inflammation medicine of preparation | |
| CN105412065A (en) | Application of Mycoleptodiscin A in preparing aseptic inflammation resisting medicine | |
| CN103393673B (en) | Application of compound in anti-aseptic inflammation drug preparation | |
| CN103356594B (en) | The application of Chukrasone B in the anti-aseptic inflammation medicine of preparation | |
| CN103356643B (en) | The application of Chukrasone A in the anti-aseptic inflammation medicine of preparation | |
| CN105434419A (en) | Use of Altertoxin IV in preparation of aseptic inflammation-diminishing drug | |
| CN105287602A (en) | Application of Trigonoliimine A in preparation of aseptic inflammation resisting medicine | |
| CN105412098A (en) | Application of Melodinine E in preparing drugs for anti-aseptic inflammation | |
| CN102988379B (en) | Application of Houttuynoid C for preparing aseptic inflammation resistant medicine | |
| CN103263545B (en) | Traditional Chinese medicine for treating seborrheic dermatitis | |
| CN103127075A (en) | Application of Aphanamixoid A to aseptic inflammation resistance medicine | |
| CN102872037B (en) | Application of Gypensapogenin B in preparing medicaments against aseptic inflammation | |
| CN106265639A (en) | Linderolide H application in preparation anti-bacteria-free inflammation | |
| CN103251582B (en) | Application of 5,7,3',4',5'-pentamethoxyl flavone in preparing analgesic and anti-inflammatory drugs | |
| CN106361747A (en) | Application of Ternatusine A in preparation of drugs for resisting aseptic inflammations | |
| CN103356537A (en) | Application of Sarcaboside B in preparation of medicines for resisting aseptic inflammation | |
| CN103393664A (en) | Application of Sarcaboside A to medicament for resisting aseptic inflammation | |
| CN104116821B (en) | A kind of medical composition and its use of anti-inflammatory and antalgic | |
| CN102357124A (en) | Chinese medicine combination with effects of detumescence and inflammatory resistance and preparation method thereof | |
| CN103251625A (en) | Application of Aspeverin in preparation of anti-bacteria-free inflammation medicines | |
| CN102988389A (en) | Application of Houttuynoid B for preparing aseptic inflammation resistant medicine | |
| CN103120658A (en) | Application of Eryngiolide A in medicine for resisting aseptic inflammation | |
| CN103127154A (en) | Application of Gypensapogenin A in medicines resisting aseptic inflammation | |
| CN107865858A (en) | Applications of the Apigenin in anti-bacteria-free inflammation is prepared | |
| CN107865882A (en) | Applications of the Orientin in anti-bacteria-free inflammation is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGYU ZHONGTAI MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHAO QIAOYING Effective date: 20150630 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150630 Address after: 312399 Zhejiang city of Shaoxing province Shangyu City Baiguan Street New Village Temple No. 3 tablets Applicant after: Shangyu city Zhong Tai medical science and technology company limited Address before: Shangyu City Songxia Town Temple Village 312365 Zhejiang city of Shaoxing province No. 1064 Applicant before: Zhao Qiaoying |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160414 Address after: Chun Xi county of Nanjing City, Jiangsu province 211300 Gaochun Town Hing Road No. 95 Patentee after: Sun Aihua Address before: 312399 Zhejiang city of Shaoxing province Shangyu City Baiguan Street New Village Temple No. 3 tablets Patentee before: Shangyu city Zhong Tai medical science and technology company limited |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170825 Address after: 432900, Xiaogan, Hubei province Xiaochang County Industrial Park South Station Road three East extension Patentee after: Hubei Nuo Kete medicine company limited-liability company Address before: Chun Xi county of Nanjing City, Jiangsu province 211300 Gaochun Town Hing Road No. 95 Patentee before: Sun Aihua |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170906 Address after: 211200 Rongchang City, Nanjing province Lishui Yong Yang Town, garden building, room 105, room 27, No. Patentee after: Bian Yuping Address before: 432900, Xiaogan, Hubei province Xiaochang County Industrial Park South Station Road three East extension Patentee before: Hubei Nuo Kete medicine company limited-liability company |
|
| TR01 | Transfer of patent right | ||
| CP02 | Change in the address of a patent holder |
Address after: 210000 No. 181 Hucuo North Road, Gulou District, Nanjing City, Jiangsu Province Patentee after: Bian Yuping Address before: 211200 Room 105, 27 Rongchang Garden, Yongyang Town, Lishui District, Nanjing City, Jiangsu Province Patentee before: Bian Yuping |
|
| CP02 | Change in the address of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190121 Address after: 201299 No. 4019 Chuansha Road, Chuansha Town, Pudong New Area, Shanghai Patentee after: Shanghai Tianlong Pharmaceutical Co., Ltd. Address before: 210000 No. 181 Hucuo North Road, Gulou District, Nanjing City, Jiangsu Province Patentee before: Bian Yuping |
|
| TR01 | Transfer of patent right |